한글목차

세계 멜록시캄 시장의 미래는 류마티스 관절염, 골관절염, 연부조직 염증, 외상성 통증, 수술 후 통증 등의 시장에서의 기회로 인해 유망한 전망을 보이고 있습니다. 세계 멜록시캄 시장은 2025년부터 2031년까지 CAGR 8.8%로 성장할 것으로 예상됩니다. 만성 염증성 질환의 유병률 증가, 비스테로이드성 항염증제(NSAID)에 대한 수요 증가, 통증 관리 솔루션에 대한 인식 개선이 이 시장의 주요 촉진요인으로 꼽힙니다.

• Lucintel의 예측에 따르면, 유형별로는 제형별 시장이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.
• 용도별로는 류마티스 관절염이 가장 높은 성장률을 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양(APAC)이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

멜록시캄 시장의 새로운 동향

멜록시캄 시장에서는 환자 치료의 고도화 요구, 안전에 대한 관심, 제네릭 의약품의 보급을 배경으로 몇 가지 새로운 추세를 볼 수 있습니다. 이러한 추세는 기존 경구용 정제에서 보다 다양하고 표적화된 제제로의 전환과 비오피오이드 계열 통증 관리 솔루션에 대한 집중도를 반영하고 있습니다.

• 첨단 약물전달 시스템 : 눈에 띄는 동향으로 서방형 정제, 외용제 등 첨단 약물전달 시스템의 개발을 들 수 있습니다. 이러한 혁신은 투여 빈도를 줄이고 전신 부작용(특히 위장 장애)을 최소화하여 환자의 복약 순응도를 높이는 것을 목표로 하고 있습니다. 이를 통해 관절염과 같은 만성질환의 장기적인 관리에 있어 보다 편리하고 안전한 치료 옵션을 제공할 수 있습니다.
• 비오피오이드계 통증 관리 : 주요 동향으로는 멜록시캄이 급성 통증 및 수술 후 통증에 대한 주요 비오피오이드계 대체 약물로 자리매김하고 있습니다. 정맥 주사를 포함한 새로운 속효성 제제가 개발 및 승인되어 오피오이드 계열 약물에 따른 의존성 및 부작용의 위험 없이 효과적인 통증 완화를 제공하고 있습니다. 이러한 추세는 전 세계적인 오피오이드 위기에 직접적으로 대응하는 것입니다.
• 제네릭 제제의 성장 : 제네릭 멜록시캄의 보급 확대에 따라 시장이 계속 형성되고 있습니다. 브랜드 제품의 특허가 만료된 후, 많은 제조업체들이 저가의 대체품을 출시했습니다. 이러한 추세는 가격 경쟁을 심화시키고, 특히 개발도상국에서 보다 광범위한 환자층이 멜록시캄을 더 쉽게 이용할 수 있도록 하여 시장 점유율을 확대하고 있습니다.
• 복합요법의 발전 : 새로운 트렌드로 멜록시캄을 주성분으로 하는 복합요법의 연구개발을 들 수 있습니다. 이는 멜록시캄을 다른 활성 성분과 결합하여 통증과 염증의 여러 측면을 동시에 표적으로 삼는 것입니다. 이러한 전략은 치료 효과를 향상시키고, 특히 복잡한 염증성 질환에 대한 보다 종합적인 치료 접근법을 제공합니다.
• 수의학 분야로의 확장 : 주목할 만한 동향으로는 수의학 분야에서의 멜록시캄의 응용 확대가 있습니다. 동물용으로 안전하고 효과적인 비스테로이드성 항염증제(NSAID)인 멜록시캄은 반려동물과 가축의 통증 및 염증 관리에 점점 더 많이 활용되고 있습니다. 이러한 응용은 동물 의료에 대한 관심이 높아지는 가운데, 시장에 새로운 성장의 길을 제시하고 있습니다.

이러한 추세는 기존 관절염 치료제를 넘어선 적용 범위 확대, 보다 안전하고 편리한 제형 제공, 제네릭 의약품 경쟁으로 인한 접근성 향상을 통해 멜록시캄 시장을 근본적으로 재편하고 있습니다. 시장은 인간과 동물의 건강 관리에 대한 진화하는 요구에 부응하는 보다 전문적이고 용도에 특화된 제품으로 전환하고 있습니다.

멜록시캄 시장의 최근 동향

약물전달 기술의 혁신과 환자의 안전과 편의성에 대한 강한 집중으로 인해 멜록시캄 시장은 여러 가지 주요한 발전이 이루어지고 있습니다. 이러한 발전은 특히 만성 통증 관리 및 수술 후 관리 분야에서 진화하는 의료 수요에 대응하기 위한 것으로, 세계 경쟁 환경과 제품 제공에 영향을 미치고 있습니다.

• 속효성 정맥주사제 : 중등도에서 중증의 급성 통증에 대한 새로운 멜록시캄 정맥주사제의 승인과 출시가 중요한 진전입니다. 이 속효성 비오피오이드 주사제는 수술 후 통증 관리에 있어 중요한 대안이 될 수 있으며, 오피오이드 의존성 감소에 기여할 수 있습니다. 특히 빠른 작용 발현이 필수적인 병원 환경에서 그 도입은 큰 영향을 미치고 있습니다.
• 서방형 정제 : 또 다른 중요한 발전은 서방형 멜록시캄 정제의 도입입니다. 이 제제는 하루 한 번 복용으로 24시간 동안 지속적인 통증 완화를 제공하도록 설계되었습니다. 이를 통해 환자의 복약 순응도를 높이고, 투약 빈도를 줄이며, 위장 장애의 위험을 최소화하여 만성 관절염의 장기적인 관리에서 보다 편리한 선택이 될 수 있습니다.
• 제네릭 의약품 경쟁 심화 : 주요 특허가 만료됨에 따라 시장에서는 제네릭 의약품의 경쟁이 심화되고 있습니다. 이번 조치로 멜록시캄의 평균 가격이 낮아져 보다 많은 환자들이 보다 합리적인 가격으로 접근할 수 있게 됐습니다. 브랜드 제품의 가격 압박을 받는 한편, 시장 규모 확대와 전체 약품 사용 확대를 촉진하는 효과도 발생합니다.
• 국소 통증용 외용 젤 : 국소 통증 치료에서 멜록시캄 외용 젤의 개발 및 도입은 큰 진전입니다. 환부에 직접 적용이 가능하기 때문에 전신 노출 및 관련 부작용을 줄이면서 대상 부위에 집중적인 완화 효과를 가져옵니다. 이 제형은 특정 관절의 골관절염과 같은 증상이 있는 환자에게 특히 유용합니다.
• 전략적 제휴 및 인수 : 제약사들은 멜록시캄 제품 포트폴리오와 지리적 확장을 위해 전략적 제휴 및 인수를 추진하고 있습니다. 특히 제네릭 제조업체 및 신약 약물전달 기술 전문 기업과의 협업은 시장 성장을 가속화하고 혁신을 촉진하며 기업의 경쟁 우위 확보에 기여하고 있습니다.

이러한 발전은 제품 라인업의 다양화, 환자의 안전성 및 편의성 향상, 시장 접근성 확대를 통해 멜록시캄 시장에 큰 영향을 미치고 있습니다. 시장은 기존의 경구용 정제에 대한 의존에서 수술 후 급성 통증부터 만성 관절염 관리까지 다양한 환자들의 니즈를 충족시키는 다양한 제제로 전환하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 멜록시캄 시장 : 종류별

• 매력 분석 : 종류별
• 성분별
• 경로별
• 제형별

제5장 세계의 멜록시캄 시장 : 용도별

• 매력 분석 : 용도별
• 류마티스 관절염
• 골관절염
• 연조직 염증
• 외상성 통증
• 수술 후 통증
• 기타

제6장 지역 분석

제7장 북미의 멜록시캄 시장

• 북미의 멜록시캄 시장 : 종류별
• 북미의 멜록시캄 시장 : 용도별
• 미국의 멜록시캄 시장
• 멕시코의 멜록시캄 시장
• 캐나다의 멜록시캄 시장

제8장 유럽의 멜록시캄 시장

• 유럽의 멜록시캄 시장 : 종류별
• 유럽의 멜록시캄 시장 : 용도별
• 독일의 멜록시캄 시장
• 프랑스의 멜록시캄 시장
• 스페인의 멜록시캄 시장
• 이탈리아의 멜록시캄 시장
• 영국의 멜록시캄 시장

제9장 아시아태평양의 멜록시캄 시장

• 아시아태평양의 멜록시캄 시장 : 종류별
• 아시아태평양의 멜록시캄 시장 : 용도별
• 일본의 멜록시캄 시장
• 인도의 멜록시캄 시장
• 중국의 멜록시캄 시장
• 한국의 멜록시캄 시장
• 인도네시아의 멜록시캄 시장

제10장 기타 지역(ROW)의 멜록시캄 시장

• ROW의 멜록시캄 시장 : 종류별
• ROW의 멜록시캄 시장 : 용도별
• 중동의 멜록시캄 시장
• 남미의 멜록시캄 시장
• 아프리카의 멜록시캄 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
• 세계의 멜록시캄 시장 최신 동향
• 전략 분석

제13장 밸류체인 전반에 걸친 주요 기업 개요

• 경쟁 분석
• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

제14장 부록

영문목차

The future of the global meloxicam market looks promising with opportunities in the rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, and post-operative pain markets. The global meloxicam market is expected to grow with a CAGR of 8.8% from 2025 to 2031. The major drivers for this market are the increasing prevalence of chronic inflammatory diseases, the rising demand for non-steroidal anti-inflammatory drugs, and the growing awareness of pain management solutions.

• Lucintel forecasts that, within the type category, by dosage form is expected to witness the highest growth over the forecast period.
• Within the application category, rheumatoid arthritis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Meloxicam Market

The meloxicam market is witnessing several emerging trends, which are driven by the need for enhanced patient care, a focus on safety, and the proliferation of generic alternatives. These trends reflect a shift from traditional oral tablets to more diverse and targeted formulations, as well as an increased focus on non-opioid pain management solutions.

• Advanced Drug Delivery Systems: A prominent trend is the development of advanced drug delivery systems, such as extended-release tablets and topical gels. These innovations aim to improve patient compliance by reducing dosing frequency and minimizing systemic side effects, particularly gastrointestinal issues. This provides a more convenient and safer treatment option for long-term management of chronic conditions like arthritis.
• Non-Opioid Pain Management: A key trend is the positioning of meloxicam as a primary non-opioid alternative for acute and post-operative pain. New fast-acting formulations, including intravenous injections, are being developed and approved to provide effective pain relief without the risks of addiction and side effects associated with opioids. This trend directly addresses the global opioid crisis.
• Growth of Generic Formulations: The market continues to be shaped by the increasing prevalence of generic meloxicam. Following the patent expiration of branded products, numerous manufacturers have introduced low-cost alternatives. This trend has intensified price competition, making meloxicam more accessible to a wider patient population and expanding its market share, especially in developing economies.
• Combination Therapies: Another emerging trend is the research and development of combination therapies involving meloxicam. This involves combining meloxicam with other active ingredients to target multiple aspects of pain and inflammation simultaneously. Such strategies aim to improve therapeutic outcomes and offer a more comprehensive treatment approach, particularly for complex inflammatory conditions.
• Expansion into Veterinary Medicine: A notable trend is the growing application of meloxicam in veterinary medicine. As a safe and effective non-steroidal anti-inflammatory drug (NSAID) for animals, meloxicam is increasingly used to manage pain and inflammation in companion animals and livestock. This application presents a new growth avenue for the market, driven by the increasing focus on animal health.

These trends are fundamentally reshaping the meloxicam market by expanding its applications beyond traditional arthritis treatment, offering safer and more convenient formulations, and increasing accessibility through generic competition. The market is moving towards more specialized, application-specific products that cater to the evolving needs of both human and veterinary healthcare.

Recent Developments in the Meloxicam Market

The meloxicam market has seen a number of key developments driven by innovations in drug delivery and a strong focus on patient safety and convenience. These advancements are aimed at addressing evolving healthcare needs, particularly in chronic pain management and post-operative care, and are impacting the competitive landscape and product offerings globally.

• Fast-Acting IV Formulation: A significant development is the approval and market availability of a new intravenous (IV) formulation of meloxicam for moderate-to-severe acute pain. This fast-acting non-opioid injectable offers a crucial alternative for post-surgical pain management, helping to reduce reliance on opioids. Its introduction is particularly impactful in hospital settings, where a rapid onset of action is essential.
• Extended-Release Tablets: Another key development is the introduction of extended-release meloxicam tablets. These formulations are designed to provide sustained pain relief over a 24-hour period with a single daily dose. This improves patient adherence, reduces dosing frequency, and helps to minimize the risk of gastrointestinal side effects, making it a more convenient option for long-term management of chronic arthritis.
• Growing Generic Competition: The market has experienced a surge in generic competition following the expiration of key patents. This development has led to a reduction in the average price of meloxicam, making it more affordable and accessible to a wider patient population. While this puts pressure on the pricing of branded products, it also drives market volume and expands the drug's overall use.
• Topical Gels for Localized Pain: The development and introduction of topical meloxicam gels represent a significant advancement for treating localized pain. These gels allow for direct application to the affected area, providing targeted relief while reducing systemic exposure and the associated side effects. This formulation is particularly beneficial for patients with conditions like osteoarthritis in specific joints.
• Strategic Partnerships and Acquisitions: Pharmaceutical companies are engaging in strategic partnerships and acquisitions to expand their meloxicam product portfolios and geographical reach. These collaborations, particularly with generic manufacturers and companies specializing in new drug delivery technologies, are accelerating market growth, fostering innovation, and helping companies to gain a competitive edge.

These developments are having a profound impact on the meloxicam market by diversifying product offerings, enhancing patient safety and convenience, and increasing market accessibility. The market is shifting from a reliance on traditional oral tablets to a more diverse range of formulations that cater to specific patient needs, from acute post-operative pain to chronic arthritis management.

Strategic Growth Opportunities in the Meloxicam Market

The meloxicam market offers several strategic growth opportunities, driven by its versatile applications and the increasing demand for effective, non-opioid pain management solutions. These opportunities are focused on expanding into new therapeutic areas, developing innovative formulations, and catering to specific patient populations, thereby enhancing market penetration and value.

• Post-Operative Pain Management: A significant growth opportunity lies in positioning meloxicam as a first-line non-opioid alternative for post-operative pain. The development of fast-acting intravenous formulations allows for immediate pain relief in a clinical setting, reducing the need for addictive opioids. This is a high-growth area, driven by global efforts to mitigate the opioid crisis.
• Topical Formulations for Arthritis: The growing demand for non-systemic treatments for localized pain presents a key opportunity for topical meloxicam gels and creams. These formulations can provide targeted relief for conditions like osteoarthritis, minimizing the risk of systemic side effects. This application addresses a large patient population seeking a safer alternative to oral NSAIDs.
• Combination Therapies for Chronic Pain: Developing meloxicam-based combination therapies offers a strategic opportunity to create more potent and comprehensive pain management solutions. By combining meloxicam with other analgesics or anti-inflammatory agents, companies can offer multi-modal pain relief, which is particularly effective for managing chronic conditions that do not respond to a single medication.
• Veterinary Applications: The veterinary pharmaceutical sector represents a promising growth opportunity for meloxicam. As pet ownership and animal healthcare expenditure rise, there is increasing demand for effective and safe pain and inflammation management in animals. Meloxicam's established efficacy makes it a strong candidate for this expanding market segment.
• Formulations for Pediatrics: A niche but important opportunity exists in developing pediatric-specific meloxicam formulations. With the approval of meloxicam for juvenile rheumatoid arthritis, there is a need for child-friendly dosage forms, such as suspensions or chewable tablets. This would address a significant unmet need and expand the drug's market to a younger patient population.

These growth opportunities are impacting the meloxicam market by driving innovation beyond its traditional use. By focusing on these strategic areas, companies can differentiate their products, capture new market segments, and ultimately solidify meloxicam's position as a versatile and essential non-opioid medication in a wide range of applications.

Meloxicam Market Driver and Challenges

The meloxicam market is a dynamic landscape shaped by various drivers that propel its growth and a set of challenges that can hinder its progress. The key drivers are rooted in global demographic shifts and the pressing need for safer pain management, while challenges arise from regulatory scrutiny and intense market competition.

The factors responsible for driving the meloxicam market include:

1. Rising Prevalence of Arthritis: The increasing global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population, is a primary driver. Meloxicam is a widely prescribed NSAID for these conditions, and as the number of patients grows, so does the demand for the drug. This demographic shift provides a solid foundation for market expansion.

2. Preference for Non-Opioid Pain Relief: A major driver is the global effort to combat the opioid crisis. Healthcare providers and patients are increasingly seeking effective non-opioid alternatives for both chronic and acute pain management. Meloxicam, with its established efficacy and favorable safety profile compared to opioids, is well-positioned to meet this demand.

3. Patent Expirations and Generic Growth: The expiration of key patents has led to a proliferation of generic meloxicam products. This has made the drug more affordable and accessible, particularly in emerging markets. The resulting increase in market volume and competition is a significant driver of overall market growth.

4. Technological Advancements: Innovations in drug delivery systems, such as extended-release and intravenous formulations, are driving market growth. These advancements improve patient convenience, efficacy, and safety, making meloxicam a more attractive option for a wider range of applications, including post-operative care.

5. Growing Healthcare Expenditure: The rise in global healthcare expenditure, particularly in emerging economies, is a key driver. Increased spending allows for better access to medications and advanced treatments, thereby boosting the demand for meloxicam and other anti-inflammatory drugs.

Challenges in the meloxicam market are:

1. Side Effect Profile: Meloxicam, like all NSAIDs, carries a risk of side effects, including gastrointestinal and cardiovascular issues. These safety concerns can limit its use in certain patient populations and necessitate careful monitoring, which poses a significant challenge to market growth.

2. Competition from Alternatives: The market is highly competitive, not only from generic versions of meloxicam but also from other NSAIDs, biologics, and novel pain therapies. Differentiating meloxicam and its new formulations in a crowded market and maintaining market share is a continuous challenge for manufacturers.

3. Strict Regulatory Environment: The development and approval of new meloxicam formulations face a stringent regulatory environment. Regulatory bodies require extensive clinical data to prove efficacy and safety, which can be a costly and time-consuming process. This creates a barrier to entry for new products and slows down innovation.

The meloxicam market is being propelled by the growing need for effective, safe, and affordable pain management solutions, driven by an aging population and the fight against the opioid crisis. However, these positive trends are tempered by the inherent safety concerns associated with NSAIDs, intense market competition, and the challenging regulatory landscape that new formulations must navigate to reach the market.

List of Meloxicam Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies meloxicam companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the meloxicam companies profiled in this report include-

• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

Meloxicam Market by Segment

The study includes a forecast for the global meloxicam market by type, application, and region.

Meloxicam Market by Type [Value from 2019 to 2031]:

• by Ingredient
• by Route
• by Dosage Form

Meloxicam Market by Application [Value from 2019 to 2031]:

• Rheumatoid Arthritis
• Osteoarthritis
• Soft Tissue Inflammation
• Traumatic Pain
• Post-Operative Pain
• Others

Country Wise Outlook for the Meloxicam Market

The meloxicam market is undergoing significant transformations, driven by a growing aging population and rising prevalence of chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis. This has spurred a shift towards new formulations and a greater emphasis on non-opioid pain management. The market is also heavily influenced by generic competition and regional regulatory dynamics, shaping pricing and market access globally.

• United States: The U.S. market is highly competitive, with a strong presence of both branded and generic meloxicam. A key development is the focus on new, fast-acting formulations, such as those for intravenous use, aimed at managing moderate-to-severe acute pain. These innovations offer a non-opioid alternative for post-operative care, addressing the national opioid crisis and meeting demand for safer pain management.
• China: The Chinese meloxicam market is experiencing rapid growth, fueled by the country's expanding healthcare infrastructure and a large, aging population. Local and international companies are increasing their presence, with a focus on producing and distributing cost-effective generic versions. This expansion is supported by government initiatives to improve healthcare access and manage the rising burden of chronic diseases.
• Germany: Germany represents a mature European market for meloxicam, characterized by a well-established healthcare system and a strong emphasis on quality and safety. The market is driven by the management of chronic conditions, with a steady demand for both oral and injectable formulations. Regulatory standards and reimbursement policies play a crucial role in shaping market dynamics and product availability.
• India: India is a fast-growing market, primarily dominated by generic meloxicam products due to their affordability. The market is propelled by a large patient base with inflammatory conditions and a growing middle class with increasing access to healthcare. Pharmaceutical companies are focusing on low-cost manufacturing and expanding their distribution networks to cater to this high-demand, price-sensitive market.
• Japan: The Japanese market is defined by its focus on technological advancements and high-quality pharmaceutical products. While the market for meloxicam is steady, there is a strong emphasis on developing and utilizing advanced drug delivery systems and formulations to improve efficacy and reduce side effects. This reflects Japan's patient-centric approach to healthcare and its advanced geriatric care needs.

Features of the Global Meloxicam Market

• Market Size Estimates: Meloxicam market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Meloxicam market size by type, application, and region in terms of value ($B).
• Regional Analysis: Meloxicam market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the meloxicam market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the meloxicam market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the meloxicam market by type (by ingredient, by route, and by dosage form), application (rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, post-operative pain, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Meloxicam Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 by Ingredient: Trends and Forecast (2019-2031)
• 4.4 by Route: Trends and Forecast (2019-2031)
• 4.5 by Dosage Form: Trends and Forecast (2019-2031)

5. Global Meloxicam Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Rheumatoid Arthritis: Trends and Forecast (2019-2031)
• 5.4 Osteoarthritis: Trends and Forecast (2019-2031)
• 5.5 Soft Tissue Inflammation: Trends and Forecast (2019-2031)
• 5.6 Traumatic Pain: Trends and Forecast (2019-2031)
• 5.7 Post-Operative Pain: Trends and Forecast (2019-2031)
• 5.8 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Meloxicam Market by Region

7. North American Meloxicam Market

• 7.1 Overview
• 7.2 North American Meloxicam Market by Type
• 7.3 North American Meloxicam Market by Application
• 7.4 United States Meloxicam Market
• 7.5 Mexican Meloxicam Market
• 7.6 Canadian Meloxicam Market

8. European Meloxicam Market

• 8.1 Overview
• 8.2 European Meloxicam Market by Type
• 8.3 European Meloxicam Market by Application
• 8.4 German Meloxicam Market
• 8.5 French Meloxicam Market
• 8.6 Spanish Meloxicam Market
• 8.7 Italian Meloxicam Market
• 8.8 United Kingdom Meloxicam Market

9. APAC Meloxicam Market

• 9.1 Overview
• 9.2 APAC Meloxicam Market by Type
• 9.3 APAC Meloxicam Market by Application
• 9.4 Japanese Meloxicam Market
• 9.5 Indian Meloxicam Market
• 9.6 Chinese Meloxicam Market
• 9.7 South Korean Meloxicam Market
• 9.8 Indonesian Meloxicam Market

10. ROW Meloxicam Market

• 10.1 Overview
• 10.2 ROW Meloxicam Market by Type
• 10.3 ROW Meloxicam Market by Application
• 10.4 Middle Eastern Meloxicam Market
• 10.5 South American Meloxicam Market
• 10.6 African Meloxicam Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Meloxicam Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Boehringer Ingelheim
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Baudax
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Perrigo
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Recro Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Iroko Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Zyla Life Sciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Axsome Therapeutics
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Orbis Biosciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Cellix Bio
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Ligand Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us